What is the clinical evidence from this study?

Study design: RCT. Population: Hypertriglyceridemia and mixed hyperlipidemia (n=582). Intervention: Plozasiran vs. Baseline. Primary outcome: Change in fasting triglycerides (TGs).

What question did this study set out to answer?

Evaluate the long-term efficacy and safety of plozasiran in patients with varying degrees of hypertriglyceridemia.

March 26, 2026American Journal of Preventive CardiologyOpen Access

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials

View Full Paper

Ask AI

Bookmark

Key result

Plozasiran sustains ~79% triglyceride reductions at 24 months in severe hypertriglyceridemia.

n=582

Why the study?

Long-term data suggested maintenance of triglyceride reductions beyond blinded treatment periods, supporting further evaluation of plozasiran across a broad spectrum of hypertriglyceridemia.

Does long-term plozasiran treatment safely sustain reductions in fasting triglycerides and atherogenic lipoproteins in patients with hypertriglyceridemia or mixed hyperlipidemia?

Population

Patients from SHASTA-2 (n = 229, severe HTG) and MUIR (n = 353, mixed hyperlipidemia)

Comparison

Assigned plozasiran dose transitioning to 25 mg Q3M

Design

Open-label extension of two randomized double-blind phase 2b trials

Follow-up

two-year

Authors

CBChristie M. Ballantyne ABAlexis BaassPreventive Cardiology RRRobert S. Rosenson

Discussion

Member takes

Implication

May support long-term plozasiran use in hypertriglyceridemia; extends evidence of sustained efficacy and safety to 24 months.

Key Points

Evaluate the long-term efficacy and safety of plozasiran in patients with varying degrees of hypertriglyceridemia.
Open-label extension of SHASTA-2 and MUIR trials
Total participants N=582 (SHASTA-2: 229; MUIR: 353)
Assessed treatment-emergent adverse events and triglyceride levels over 24 months
In SHASTA-2, mean TG reductions were -77% (Month 12) and -79% (Month 24), from baseline.
In MUIR, mean TG reductions were -62% (Month 12) and -63% (Month 24), compared to baseline.
Stable HbA1c levels were observed with common TEAEs including diabetes, COVID-19, and upper respiratory tract infections.

Study Design

Type

RCT (n=582)

Blinding

Open-label

Structured PICO

Does long-term plozasiran treatment safely sustain reductions in fasting triglycerides and atherogenic lipoproteins in patients with hypertriglyceridemia or mixed hyperlipidemia?

Population

582 patients from two phase 2b trials: SHASTA-2 (n=229) with severe hypertriglyceridemia (TG >500 mg/dL) and MUIR (n=353) with mixed hyperlipidemia (TG 150–499 mg/dL, LDL-C ≥ 70 mg/dL or non-HDL-C ≥ 100 mg/dL).

Intervention

Plozasiran transitioned to a regimen of 25 mg every 3 months (Q3M) over 24 months.

Outcome

Treatment-emergent adverse events (TEAEs), change in fasting TGs, and atherogenic lipoproteins over a two-year follow-up.surrogate

Long-term open-label treatment with plozasiran provides sustained and substantial reductions in triglycerides across a broad spectrum of hypertriglyceridemia with a stable safety profile.

Cite This Study

Ballantyne et al. (2026) conducted an RCT in Hypertriglyceridemia and mixed hyperlipidemia (n=582). Plozasiran vs. Baseline was evaluated on Change in fasting triglycerides (TGs). In an open-label extension, plozasiran 25 mg Q3M produced sustained mean triglyceride reductions from baseline of 79% in severe hypertriglyceridemia and 63% in mixed hyperlipidemia at 24 months.

synapsesocial.com/papers/69c4cc02fdc3bde4489174e3 https://doi.org/10.1016/j.ajpc.2026.101523

View Full Paper

Ask AI

Bookmark

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Also Consider

Also Consider